Complexes containing a labeled polypeptide and an antibody, and the use of such complexes as research, diagnostic, and clinical tools, are described herein.

An in vitro method is disclosed for detecting an antibody to p53 (anti-p53 antibody) in a sample, the method comprising: incubating a sample to be analyzed with a p53 capture antigen and a p53 detection antigen, whereby a complex comprising the p53 capture antigen, the anti-p53 antibody and the p53 detection antigen is formed, separating the complex formed from unbound detection antigen and measuring the complex obtained via the detection antigen comprised therein, thereby detecting the anti-p53 antibody comprised in the sample.

Disclosed are compositions and methods to detect proteins associated with Head and Neck Cancer, generally, or more particularly, biomarkers of Head and Neck Squamous Cell Carcinoma (HNSCC). Such markers may be useful to allow individuals susceptible to HNSCC to manage their lifestyle and/or medical treatment to avoid further progression of disease.

Methods are provided for treating a subject having a MYC-driven neoplasia. Aspects of the methods include administering to the subject an amount of an inhibitor of a target gene effective to treat the subject for the MYC-driven neoplasia. Methods are also provided for identifying a MYC-dependent target gene in a MYC-driven neoplasia. Aspects of the method include identifying the MYC-dependent target gene based on a phenotype detected in a first tumor cell line conditionally expressing MYC that is absent or quantitatively different in a second tumor cell line conditionally repressing MYC when the two cell lines are contacted with a CRISPR-based gene silencing agent. Kits and cell lines for practicing the methods of the disclosure are also provided.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Methods are provided for the analysis, including the serial analysis, of very small samples of tissue. The methods utilize a nanofluidic proteomic immunoassay (NIA) to quantify total and low-abundance protein isoforms in a small amount of lysate. NIA detection accurately measure oncoprotein expression and activation in limited clinical specimens, including isoforms that differ in post-translational modifications, such as phosphorylation, and the like. The NIA detection method combines isoelectric protein focusing and antibody detection in a nanofluidic system.

There are three current challenges to checking Cancer metastasis. These challenges mitigate against effective development and design of a comprehensive and appropriate utility diagnostic. The challenges include: a) Origin of Circulating tumor cells (CTC) and Tumor spread mechanism of dissemination), b) The role of normal tissue in metastasis, and c) Resistance to drug. This present invention is a comprehensive diagnostic that provides a method for predicting and diagnosing Cancer spread, as well as determine efficacy of therapy in a patient sample. The Cancer Diagnostic Metastasis Panel (CDMP) is a dialogic invention that is also a reflection of key communication variables of intercellular and intra-cellular agents, based on cell behavior including non-adherence or adherence to Tradition; as a shared behavioral practice performed repeatedly over time, that depends in part on socially mutually aided learning for its generation in and among cells and in specific environment (see below), incapacity of the Host Defense System as well as perceptions of the changing character of the environments. There is a system of incentives actuated by conditions of nutrient poverty and dependency. Morphologically, new structures contend with the old.

The Cancer Diagnostic Metastasis Panel (CDMP) relies on the spontaneous recognition of the kinetics of the Circulatory System, and the almost spontaneous selection response of the Host Defense System (Immunologic System) in specific microenvironment based on incapacity; especially proximal (near) to the parent tumor cell. There is an energy to energy correlation measurable by energy-time specific levels and wavelengths. The spontaneity is enabled by signal energy resonance in the two systems (apple to apple) in recognition of the changing character of a field or microenvironment.

There are key elements which monitor the dialogic environment, and measurable benchmarks which serve as biomarkers.

The present invention provides compositions and methods for treating cancer with peptide nucleic acid agents. In some embodiments, the present invention provides methods and compositions relating to peptide nucleic acid agents that target oncogenes. For example, the present invention provides compositions, including pharmaceutical compositions, comprising agents specific for BRAF V600E inhibition, or fragments or characteristic portions thereof. The present invention further provides various therapeutic and/or diagnostic methods of using BRAF V600E specific peptide nucleic acid agents and/or compositions.

The present disclosure provides diagnostic methods useful for predicting a patient's response to alvocidib and guiding a physician decision to administer alvocidib to the patient.

A nanoimmunoassay (NIA) is applied to quantify analytes, including without limitation proteins and isoforms of proteins involved in oncogenic or metabolic signaling pathways, in a small amount of lysate from a tissue sample. Samples of interest for NIA include without limitation blood or solid tumor microbiopsy samples, such as fine needle aspirate (FNA) or circulating tumor cells. Samples may be taken at a single timepoint, or may be taken at multiple timepoints. Samples may be as small as 100,000 cells, as small as 5000 cells, as small as 1000 cells, as small as 100 cells, as small as 50 cells, as small as 25 cells or less. The NIA detection method combines size separation of proteins or isoelectric protein focusing and antibody detection in a microfluidic system.